These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 16551136)

  • 21. Onco-Multi-OMICS Approach: A New Frontier in Cancer Research.
    Chakraborty S; Hosen MI; Ahmed M; Shekhar HU
    Biomed Res Int; 2018; 2018():9836256. PubMed ID: 30402498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor markers: the potential of "omics" approach.
    Sikaroodi M; Galachiantz Y; Baranova A
    Curr Mol Med; 2010 Mar; 10(2):249-57. PubMed ID: 20196723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent progress in biomolecular engineering.
    Ryu DD; Nam DH
    Biotechnol Prog; 2000; 16(1):2-16. PubMed ID: 10662483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer.
    Brennan DJ; Kelly C; Rexhepaj E; Dervan PA; Duffy MJ; Gallagher WM
    Cancer Genomics Proteomics; 2007; 4(3):121-34. PubMed ID: 17878516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.
    Sabbah M; Emami S; Redeuilh G; Julien S; Prévost G; Zimber A; Ouelaa R; Bracke M; De Wever O; Gespach C
    Drug Resist Updat; 2008; 11(4-5):123-51. PubMed ID: 18718806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Where are we in genomics?
    Hocquette JF
    J Physiol Pharmacol; 2005 Jun; 56 Suppl 3():37-70. PubMed ID: 16077195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IT Future of Medicine: from molecular analysis to clinical diagnosis and improved treatment.
    Zazzu V; Regierer B; Kühn A; Sudbrak R; Lehrach H
    N Biotechnol; 2013 May; 30(4):362-5. PubMed ID: 23165094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in the development of genetic markers for the diagnosis of disease and drug response.
    Halapi E; Hakonarson H
    Expert Rev Mol Diagn; 2002 Sep; 2(5):411-21. PubMed ID: 12271813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional genomics and proteomics in the clinical neurosciences: data mining and bioinformatics.
    Phan JH; Quo CF; Wang MD
    Prog Brain Res; 2006; 158():83-108. PubMed ID: 17027692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology.
    Cronin M; Ross JS
    Biomark Med; 2011 Jun; 5(3):293-305. PubMed ID: 21657839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SIGMA: a system for integrative genomic microarray analysis of cancer genomes.
    Chari R; Lockwood WW; Coe BP; Chu A; Macey D; Thomson A; Davies JJ; MacAulay C; Lam WL
    BMC Genomics; 2006 Dec; 7():324. PubMed ID: 17192189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of expression genomics for predicting treatment response in cancer.
    Chin KV; Alabanza L; Fujii K; Kudoh K; Kita T; Kikuchi Y; Selvanayagam ZE; Wong YF; Lin Y; Shih WC
    Ann N Y Acad Sci; 2005 Nov; 1058():186-95. PubMed ID: 16394136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New omics information for clinical trial utility in the primary setting.
    Damia G; Broggini M; Marsoni S; Venturini S; Generali D
    J Natl Cancer Inst Monogr; 2011; 2011(43):128-33. PubMed ID: 22043059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A tiling resolution DNA microarray with complete coverage of the human genome.
    Ishkanian AS; Malloff CA; Watson SK; DeLeeuw RJ; Chi B; Coe BP; Snijders A; Albertson DG; Pinkel D; Marra MA; Ling V; MacAulay C; Lam WL
    Nat Genet; 2004 Mar; 36(3):299-303. PubMed ID: 14981516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data.
    Piñeiro-Yáñez E; Reboiro-Jato M; Gómez-López G; Perales-Patón J; Troulé K; Rodríguez JM; Tejero H; Shimamura T; López-Casas PP; Carretero J; Valencia A; Hidalgo M; Glez-Peña D; Al-Shahrour F
    Genome Med; 2018 May; 10(1):41. PubMed ID: 29848362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uncharacterized/hypothetical proteins in biomedical 'omics' experiments: is novelty being swept under the carpet?
    Pawłowski K
    Brief Funct Genomic Proteomic; 2008 Jul; 7(4):283-90. PubMed ID: 18641417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging translational bioinformatics: knowledge-guided biomarker identification for cancer diagnostics.
    Phan JH; Yin-Goen Q; Young AN; Wang MD
    Annu Int Conf IEEE Eng Med Biol Soc; 2009; 2009():4162-5. PubMed ID: 19964620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Translational bioinformatics approaches for systems and dynamical medicine.
    Yan Q
    Methods Mol Biol; 2014; 1175():19-34. PubMed ID: 25150864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.